Research

Washington D.C., Feb. 18, 2025- The Global Alzheimer’s Platform Foundation ® (GAP) is gravely concerned over news of terminations of key leaders at the National Institute of Health and the Federal Drug Administration along with the firing of thousands of employees from the Department of Health and Human Services over the weekend. John Dwyer, the […]

Washington D.C., Feb. 18, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Roche to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images as well as numerous races and ethnicities […]

Ralph Kern, MD, MHSc, CMO of Cognito Therapeutics, discusses scaling up clinical trials, integrating patient centricity and transitioning from therapeutics to device treatments. February 13, 2025 Tell us about the scientific foundation behind the Spectris ADTM device. Our non-invasive investigational Spectris ADTM device evokes 40 Hz brain gamma oscillations through audiovisual stimulation. It’s delivered in […]

The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce a collaboration with the Biomarkers of Aging Consortium, a consortium dedicated to the developing and validating biomarkers for aging and longevity. Through a memorandum of understanding, the consortium, led by scholars from Harvard University, will gain early access to Bio-Hermes-001 data to investigate the potential for […]

January 30, 2025 10:24 PM in News – Local By: Lily Celeste The Rio Grande Valley has one of the highest rates of Alzheimer’s in the country, and a clinic in Rio Grande city is attempting to find out why. Dina Ximenez said she’s been volunteering for three years for Alzheimer’s studies conducted by El Faro Health Clinic […]

Collaboration to accelerate the investigation of Alzheimer’s disease biomarkers with early access to Bio-Hermes-001 data  Washington D.C., Jan. 30, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce a collaboration with the Biomarkers of Aging Consortium, a consortium dedicated to the developing and validating biomarkers for aging and longevity. Through a memorandum […]

By Anjelica Rubin – Technology/Tampa Bay Inno reporter, Tampa Bay Business Journal Jan 27, 2025 Updated Jan 28, 2025 5:39pm EST Just over one year after being acquired to help build a clinical research center, Tampa-based Axiom Brain Health celebrated the next chapter in its neurodegenerative research at the launch of its new site on Jan. 23.  The expansion […]

Washington D.C., Jan. 27, 2025– Global Alzheimer’s Platform Foundation® (GAP) applauds the U.S. Food and Drug Administration (FDA)’s approval of IV maintenance dosing for the treatment LEQEMBI®. With this approval, after a patient completes 18 months of once every two weeks initiation phase, a transition to the maintenance dosing regimen of once every four weeks […]

Tampa, Fla. Jan. 24, 2025—Axiom Brain Health (Axiom) and the Global Alzheimer’s Platform Foundation® (GAP) celebrated the next chapter in neurodegenerative research at the launch of the newly renovated site on Thursday, January 23. The expansion of the research facility accommodates the growing need for more research of Alzheimer’s, Multiple Sclerosis, Parkinson’s, and other life-threatening […]

Washington D.C., Jan. 23, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Beckman Coulter Diagnostics as a strategic partner in the Bio-Hermes-002 study. This first-time collaboration will enhance this unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images […]

By Austin Montgomery| December 11, 2024 Global Alzheimer’s Platform Foundation (GAP) has partnered with Eli Lilly and Company (NYSE: LLY) for a study comparing blood tests that could help predict and diagnose Alzheimer’s disease. The Bio-Hermes-002 study looks to increase participation of underrepresented older adults within typical Alzheimer’s clinical research, with at least 25% participation earmarked […]

Some turn to clinical trials to access breakthrough drugs By Cindy Krischer Goodman | cgoodman@sunsentinel.com | South Florida Sun Sentinel UPDATED: December 11, 2024 at 8:00 AM EST The federal Food & Drug Administration has approved two new Alzheimer’s medications that can offer people more time to live normally, but accessing them in Florida is complicated. Hold-ups related to insurance […]

Citizen Scientists Suzanne and Mike O’Brien of #GAPNet site JEM Research Institute

ViewMind Precision Neurological Assessments ViewMind Digital BiomarkerPublished 7:31 AM EST, December 10, 2024Share To Enhance Alzheimer’s Diagnosis Through Diverse Biomarker Analysis “We expect ViewMind’s promising technology to offer the field alternative methods for detecting and diagnosing Alzheimer’s disease.”— John Dwyer, President of the Global Alzheimer’s Platform Foundation NEW YORK CITY, NY, UNITED STATES, December 10, […]

Washington D.C., Dec. 9, 2024 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Eli Lilly and Company (Lilly) to the Bio-Hermes-002 study. This collaboration will enrich the unique, observational platform study that compares blood-based and digital biomarkers across a broad range of races and ethnicities that may help predict and diagnose Alzheimer’s […]

Washington D.C., Nov. 26, 2024- The Centers for Medicare & Medicaid Services (CMS) released the Clinical Laboratory Fee Schedule (CLFS) 2025 Final Rate Determinations yesterday, unveiling that clinically critical codes for the reimbursement of Alzheimer neurological biomarker blood tests have been referred to the process known as “gapfill.” Earlier this year, the preliminary recommendation for […]

By ActionNewsJax.com News Staff, November 18, 2024 at 5:32 pm EST Jacksonville Center for Clinical Research just joined the Global Alzheimer’s Platform Foundation’s national network of research centers. According to a news release, the JCCR has conducted more than 1,000 clinical trials over 25 years. Global Alzheimer’s Platform President John Dwyer said the organization wants to […]

Washington D.C., Nov. 18, 2024- Global Alzheimer’s Platform Foundation® (GAP) is welcoming a new clinical research site into its international network of best-in-class research sites, Jacksonville Center for Clinical Research of Jacksonville, Florida. Jacksonville Center for Clinical Research (JCCR) is a premier clinical research site, having conducted more than 1,000 clinical trials over 25 years with […]

Washington D.C., Nov. 4, 2024 – Global Alzheimer’s Platform Foundation® (GAP) applauds Eisai and Biogen on the completion of the rolling submission of the application to the U.S. Food and Drug Administration (FDA) for the subcutaneous maintenance dosing of Leqembi. If approved, this autoinjector could greatly improve the patient experience, reducing the need for biweekly one-hour visits […]

Contify Life Science News Nov 3 • 11:52 PM *Cognivue’s participation in the study will help predict underlying AD pathologies and analyze MRI, neuroinflammation, and longitudinal data. Oct. 30– Cognivue issued the following news release:. Its proven ability to distinguish between cognitively normal individuals, those with MCI, and mild dementia— regardless of amyloid status., Validated […]

By Robbie Owens, November 1, 2024 / 6:05 PM CDT / CBS Texas DALLAS – If you dare, just look at the numbers associated with Alzheimer’s: nearly 7 million Americans are diagnosed with the disease right now. According to the Alzheimer’s Association, the potential lifetime impact is 1 in 3. Gail Youngdale is one of them. “My mother […]

Oct 30, 2024 | staff reporterSave for later NEW YORK – The Global Alzheimer’s Platform (GAP) Foundation has launched the Bio-Hermes-002 study, in which it will continue to explore biomarkers that can predict the likelihood that a patient has amyloid and tau accumulations in their brains, signaling a potential Alzheimer’s diagnosis. The Alzheimer’s research-focused nonprofit announced the […]

Global Alzheimer’s Platform Foundation Announces Strategic Partnerships for the Transformative Bio-Hermes-002 Study   Washington D.C., Oct. 28, 2024 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome the initial strategic partners in the Bio-Hermes-002 study. These collaborations will enhance the unique, observational platform study that compares blood-based and digital biomarkers across a broad range […]

By Eleanore Catolico, 10/23/24 Renee Stamper, shown here with a portrait of her mother, has joined 15 clinical trials in eight years. (Photo by Alejandro Ugalde Sandoval)On Christmas Eve 2014, a speeding car clipped the bumper of a Detroit city bus in the early morning darkness. Renee Stamper, the bus driver, spun on the road.  After […]